Double-blind, Randomized, Vehicle-controlled Proof of Concept Study on the Efficacy, Safety, Local Tolerability, PK and Pharmacodynamics of Multiple Topical Administrations of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas.
Latest Information Update: 02 Nov 2015
At a glance
- Drugs Sonidegib (Primary)
- Indications Basal cell cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
Most Recent Events
- 29 Oct 2015 Time frame for primary endpoint has changed from 12 weeks to day 43 according to ClinicalTrials.gov.
- 29 Oct 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 06 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.